1.	Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis Phase: Phase III, Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: METC 191.137/2000/088, NCT00263315
2.	Phase III Randomized, Double-Blind Study of Liposomal Amphotericin B vs Standard Formulation Amphotericin B for Empiric Treatment of Persistent Febrile Neutropenia Unresponsive to Broad Spectrum Antibacterial Agents (Summary Last Modified 11/95) Phase: Phase III Type: Supportive care Status: Completed Age: 2 to 80 Sponsor: NCI Protocol IDs: NCI-95-C-0131A
3.	Phase III Randomized Study of Voriconazole Compared to Liposomal Amphotericin B as Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia (Summary Last Modified 09/1999) Phase: Phase III Type: Supportive care Status: Completed Age: 12 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NCI-98-C-0063, PFIZER-150-603
4.	Phase III Randomized Study of Liposomal Amphotericin B with or without Sargramostim in Patients with Invasive Fungal Infections Entered into Protocols MRC-LEUK-AML11, AML12, or UKALLXII (Summary Last Modified 05/2000) Phase: Phase III Type: Supportive care Status: Closed Age: 15 and over Sponsor: Protocol IDs: MRC-LEUK-IFI, EU-97030, NCT00003315
5.	Phase III Randomized Study of Amphotericin B-Liposomal Formulation Initiated 72-84 Hours vs 144-156 Hours After Onset of a Febrile Episode in Cancer Patients With Granulocytopenia and Persistent Unexplained Fever Refractory to Antibacterials Phase: Phase III Type: Supportive care Status: Closed Age: Not specified Sponsor: Other Protocol IDs: EORTC-19951, NCT00003938
6.	Phase III Randomized Study of Caspofungin Acetate Versus Amphotericin B Liposomal in Patients With Persistent Fever and Neutropenia Following Treatment for Cancer Phase: Phase III Type: Supportive care Status: Closed Age: 16 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-00085, MERCK-026-01, NCI-G00-1898, NCT00008359
7.	Phase I/II Study of Amphotericin B-Lipid Complex (AmBisome) in Immunocompromised Pediatric Patients with Definitive or Probable Invasive Fungal Infection (Summary Last Modified 01/98) Phase: Phase II, Phase I Type: Supportive care Status: Closed Age: 1 to 17 Sponsor: NCI Protocol IDs: NCI-97-C-0013
8.	Phase I/II Pilot Study of Amphotericin-B Lipid Complex in the Treatment of Hepatosplenic Candidiasis in Children with Neoplastic Disease Phase: Phase II, Phase I Type: Supportive care Status: Completed Age: 2 to 18 Sponsor: NCI Protocol IDs: NCI-92-C-0047B, NCI-T92-0001N, T92-0001
9.	MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients Phase: Phase II Type: Supportive care Status: Completed Age: 2 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: 2004_101, Formerly-0404ETPP, MK0991-044, NCT00082537
10.	Phase I Study of Liposomal Amphotericin B in Adult Cancer Patients Receiving Antineoplastic Therapy or Bone Marrow Transplantation (Summary Last Modified 07/95) Phase: Phase I Type: Supportive care Status: Completed Age: 13 to 80 Sponsor: Protocol IDs: NCI-94-C-0120D
11.	Phase I Study to Determine a Maximum Tolerated Dose of Liposomal Amphotericin B in Patients with Proven or Presumptive Aspergillosis or Infections Due to Other Filamentous Fungi (Summary Last Modified 10/97) Phase: Phase I Type: Supportive care Status: Closed Age: 18 to 80 Sponsor: NCI Protocol IDs: NCI-97-C-0001
12.	Multicenter Study of Liposomal Amphotericin B in Immunocompromised Patients with Definitive or Probable Invasive Aspergillosis (Summary Last Modified 09/95) Phase: No phase specified Type: Supportive care Status: Closed Age: under 18 Sponsor: Protocol IDs: NCI-95-C-0147
13.	Randomized, Multicenter Study of Liposomal Amphotericin B (1 mg/kg vs 4 mg/kg) in the Treatment of Neutropenic Patients with Invasive Aspergillosis Phase: No phase specified Type: Supportive care Status: Closed Age: over 1 Sponsor: Protocol IDs: EORTC-19923